Mode
Text Size
Log in / Sign up
Phase 3 N=348 Randomized Single-blind Health Services Research

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis · Indeterminate Colitis

Enrolled (actual)
348
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Harvey Bradshaw Index — 3.7; 3.2; 4.2 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Home Monitoring (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Maryland, Baltimore
Primary completion
Jul 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Harvey Bradshaw Index
3.7; 3.2; 4.2
PRIMARY
Inflammatory Bowel Disease Questionnaire
179.3; 179.2; 181.5
SECONDARY
Health Care Utilization
2435; 2167; 2481

Summary

Improved methods are needed to monitor patients with inflammatory bowel disease. Telemedicine has shown promise in patients with other chronic diseases; pilot testing in our patients with inflammatory bowel disease demonstrated that the technology was feasible and improved clinical outcomes. The telemedicine system for patients with inflammatory bowel disease (Tele-IBD) should improve outcomes for patients, improve access to care in areas with limited resources, and decrease health care costs.

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of Crohn's disease, ulcerative colitis or indeterminate colitis

Exclusion Criteria

  • Cannot comprehend simple instructions in English
  • Inability to comply with the study protocol (i.e., active drug or alcohol abuse or history of nonadherence to medical visits and/or medications)
  • Presence of an ileostomy, colostomy, ileoanal j pouch anastomosis or ileorectal anastomosis
  • Imminent surgery
  • History of short bowel syndrome
  • No flares of disease in last two years
  • Uncontrolled medical or psychiatric disease Degenerative neurologic condition Unstable angina Class III/IV congestive heart failure Severe asthma or chronic obstructive pulmonary disease Symptomatic peripheral vascular disease Chronic renal insufficiency (creatinine > 2.0) Malignancy within the last 5 years (excluding squamous or basal cell cancers of the skin) Poorly controlled depression, mania, and schizophrenia Active infection Acquired immunodeficiency syndrome
  • Pregnancy
  • Age less than 18 years.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01692743). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search